Canada Semaglutide Market Size & Outlook, 2026-2035
The semaglutide market in Canada is expected to reach a projected revenue of US$ 4,034.8 million by 2035. A compound annual growth rate of 12.28% is expected of Canada semaglutide market from 2026 to 2035.
Revenue, 2025 (US$M)
$1,300.3
Estimate, 2026 (US$M)
$1,422.9
Forecast, 2035 (US$M)
$4,034.8
CAGR, 2026 - 2035
12.3%
Global Market
Related Markets
Canada semaglutide market highlights
- The Canada semaglutide market generated a revenue of USD 1,300.3 million in 2025 and is expected to reach USD 4,034.8 million by 2035.
- The Canada market is expected to grow at a CAGR of 12.28% from 2026 to 2035.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2025.
- Rybelsus (oral semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
Semaglutide market data book summary
| Market revenue in 2025 | USD 1,300.3 million |
| Market revenue in 2035 | USD 4,034.8 million |
| Growth rate | 12.28% (CAGR from 2026 to 2035) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Rybelsus (oral semaglutide) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
| Key market players worldwide | Novo Nordisk A/S ADR, Eli Lilly and Co, Viking Therapeutics Inc, Lexicon Pharmaceuticals, Biocon, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, Canada accounted for 3.8% of the global semaglutide market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2035.
- In North America, U.S. semaglutide market is projected to lead the regional market in terms of revenue in 2035.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 629.4 million by 2035.
No credit card required*
Publish Date: Apr 16, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Semaglutide Market Scope
Semaglutide Market segmentation & scope
Semaglutide Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | www.biocon.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | www.vikingtherapeutics.com |
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | www.lexpharma.com |
Canada Semaglutide Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Semaglutide Market Outlook will help companies and investors design strategic landscapes.
Ozempic (Semaglutide) was the largest segment with a revenue share of 92.51% in 2025.
Horizon Databook has segmented the Canada semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2021 to 2035.
- Canada Semaglutide Market Product Outlook (Revenue, USD Million , 2021-2035)
- Ozempic (semaglutide)
- Wegovy (semaglutide)
- Rybelsus (oral semaglutide)
- Others
- Canada Semaglutide Market Application Outlook (Revenue, USD Million , 2021-2035)
- Type 2 Diabetes Mellitus
- Obesity
- Canada Semaglutide Market Route of Administration Outlook (Revenue, USD Million , 2021-2035)
- Parenteral
- Oral
- Canada Semaglutide Market Distribution Channel Outlook (Revenue, USD Million , 2021-2035)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Reasons to subscribe to Semaglutide Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Semaglutide Market Outlook databook
- Our clientele includes a mix of Semaglutide Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Semaglutide Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Semaglutide Market Outlook from 2021 to 2035, including revenue numbers, major trends, and company profiles.
Canada Semaglutide Market, 2021-2035 (US$M)
Canada semaglutide market statistics, by product, 2021-2035 (US$M)
